GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (CHIX:PEGc) » Definitions » Cyclically Adjusted PS Ratio

Pharma Equity Group A/S (CHIX:PEGC) Cyclically Adjusted PS Ratio : (As of May. 05, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Pharma Equity Group A/S Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Pharma Equity Group A/S Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Pharma Equity Group A/S's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Cyclically Adjusted PS Ratio Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Pharma Equity Group A/S Quarterly Data
Mar16 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Pharma Equity Group A/S's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Pharma Equity Group A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Cyclically Adjusted PS Ratio falls into.



Pharma Equity Group A/S Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Pharma Equity Group A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Pharma Equity Group A/S's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0/116.7000*116.7000
=0.000

Current CPI (Dec. 2023) = 116.7000.

Pharma Equity Group A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201103 3.876 95.800 4.722
201106 3.747 96.100 4.550
201109 2.566 96.300 3.110
201112 2.543 96.300 3.082
201203 1.730 98.300 2.054
201206 1.950 98.200 2.317
201209 2.077 98.700 2.456
201212 1.259 98.300 1.495
201303 0.000 99.300 0.000
201306 0.000 99.100 0.000
201309 0.000 99.200 0.000
201312 0.000 99.000 0.000
201403 0.000 99.600 0.000
201406 0.000 99.700 0.000
201409 0.000 99.700 0.000
201412 0.000 99.400 0.000
201503 0.000 100.200 0.000
201506 0.000 100.300 0.000
201509 0.000 100.200 0.000
201512 0.000 99.800 0.000
201603 0.000 100.200 0.000
201606 0.000 100.600 0.000
201612 0.000 100.300 0.000
201706 0.000 101.200 0.000
201712 0.000 101.300 0.000
201806 0.000 102.300 0.000
201812 0.000 102.100 0.000
201906 0.000 102.900 0.000
201912 0.000 102.900 0.000
202006 0.000 103.200 0.000
202012 0.000 103.400 0.000
202106 0.000 105.000 0.000
202112 0.000 106.600 0.000
202206 0.000 113.600 0.000
202209 0.000 116.400 0.000
202212 0.000 115.900 0.000
202303 0.000 117.300 0.000
202306 0.000 116.400 0.000
202309 0.000 117.400 0.000
202312 0.000 116.700 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Pharma Equity Group A/S  (CHIX:PEGc) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Pharma Equity Group A/S Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (CHIX:PEGC) Business Description

Traded in Other Exchanges
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.

Pharma Equity Group A/S (CHIX:PEGC) Headlines

No Headlines